HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- ‘Silver tsunami’ requires ‘all-hands-on-deck’ approach to cancer survivorship
-
- American College of Surgeons’ Commission on Cancer names chairman
- Clinicians to President-elect Trump: Embrace compromise, collaboration and the value proposition
- ‘Cures’ Act ‘momentous’ for cancer research
- MD Anderson names pediatrics department chairman
- Valuing communication and communicating value: Staying in touch with our patients’ priorities John Sweetenham, MD, FRCP, FACP
- FDA approves Avastin for ovarian, fallopian tube, peritoneal cancers
- Adjuvant girentuximab fails to provide clinical benefit in clear cell renal cell carcinoma
- High ligand expression predicts panitumumab benefit for RAS wild-type colorectal cancer
-
- White wine may increase risk for melanoma
- Addition of ibandronate to adjuvant hormonal therapy shows no benefit in early breast cancer
- CPX-351 effectively provides bridge to transplantation in poor-risk AML
- Crizanlizumab reduces sickle cell–related pain crises
- Nivolumab, ipilimumab yield mixed results in myelodysplastic syndrome
- Is it feasible to require enrollment of elderly patients in oncology clinical trials?